TG Therapeutics, Inc.
TGTX
$48.74
$0.801.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -72.40% | 290.85% | -1.26% | 9,974.61% | 309.75% |
| Total Depreciation and Amortization | 307.69% | 300.00% | 133.33% | 54.55% | -31.58% |
| Total Amortization of Deferred Charges | -17.14% | -5.40% | -1.69% | -25.27% | -49.42% |
| Total Other Non-Cash Items | 79.61% | 120.23% | 257.76% | -2,391.32% | 81.48% |
| Change in Net Operating Assets | 108.36% | -43.72% | 26.67% | -103.34% | -244.50% |
| Cash from Operations | 428.01% | 37.68% | 176.67% | -89.70% | 34.32% |
| Capital Expenditure | -597.62% | -104.00% | -219.05% | -233.33% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 133.49% | 23.98% | -198.49% | 598.85% | -323.80% |
| Cash from Investing | 125.80% | 23.74% | -199.05% | 596.71% | -326.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.32% | 3,533.33% | 85.61% | -100.00% | 220.00% |
| Repurchase of Common Stock | 100.00% | -1,533.06% | 100.00% | -3,540.86% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 101.32% | 6,504.93% | 117.42% | -158.19% | -4,872.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,446.38% | 860.34% | 131.90% | -148.74% | -140.33% |